Ibalizumab biosimilar - Oneness Biotech
Alternative Names: FB-121Latest Information Update: 28 Feb 2023
Price :
$50 *
At a glance
- Originator Fountain BioPharma
- Developer Oneness Biotech
- Class Antiretrovirals; Monoclonal antibodies
- Mechanism of Action CD4 antigen inhibitors; HIV fusion inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in HIV-infections in China (Parenteral)
- 10 Dec 2014 Preclinical trials in HIV infections in China (Parenteral)